147 related articles for article (PubMed ID: 32295692)
1. Evaluation of adverse events associated with filgrastim originator and biosimilar using a spontaneous reporting system database.
Niinomi I; Hosohata K; Oyama S; Inada A; Wakabayashi T; Iwanaga K
Pharmazie; 2020 Apr; 75(4):151-153. PubMed ID: 32295692
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.
Kobayashi T; Kamada I; Komura J; Toyoshima S; Ishii-Watabe A
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):917-924. PubMed ID: 28612945
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database.
Niinomi I; Hosohata K; Mori Y; Yamaguchi Y; Wakabayashi T; Uchida M; Iwanaga K
J Pharm Health Care Sci; 2019; 5():21. PubMed ID: 31608149
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
[TBL] [Abstract][Full Text] [Related]
5. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.
Sato K; Ishiyama K; Aoki G; Maruyama H; Tsuji N; Tanabe M; Zaimoku Y; Sato H; Yamazaki H; Yamaguchi M; Takami A; Nakao S
Int J Hematol; 2019 Dec; 110(6):648-653. PubMed ID: 31542851
[TBL] [Abstract][Full Text] [Related]
8. Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data.
Rastogi S; Shukla S; Sharma AK; Sarwat M; Srivastava P; Katiyar T; Kalaiselvan V; Singh GN
Toxicol Appl Pharmacol; 2020 May; 395():114976. PubMed ID: 32222375
[TBL] [Abstract][Full Text] [Related]
9. Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
Fruehauf S; Otremba B; Stötzer O; Rudolph C
Adv Ther; 2016 Nov; 33(11):1983-2000. PubMed ID: 27743353
[TBL] [Abstract][Full Text] [Related]
10. Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study.
Tamura K; Hashimoto K; Nishikawa K
J Infect Chemother; 2018 May; 24(5):363-369. PubMed ID: 29398477
[TBL] [Abstract][Full Text] [Related]
11. Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Tanni KA; Truong CB; Almahasis S; Qian J
BioDrugs; 2021 Mar; 35(2):239-254. PubMed ID: 33439472
[TBL] [Abstract][Full Text] [Related]
12. A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.
Hegg R; Mattar A; Matos-Neto JN; Pedrini JL; Aleixo SB; Rocha RO; Cramer-Junior RP; van-Eyll-Rocha S
Clinics (Sao Paulo); 2016 Oct; 71(10):586-592. PubMed ID: 27759847
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
[TBL] [Abstract][Full Text] [Related]
14. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
[TBL] [Abstract][Full Text] [Related]
16. Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.
Abboud CN; Lang N; Fung H; Lammerich A; Buchner A; Liu P; Mueller U; Pettengell R; Diel IJ; Link H; Pathak A
Support Care Cancer; 2019 Jul; 27(7):2569-2577. PubMed ID: 30443809
[TBL] [Abstract][Full Text] [Related]
17. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
18. First Pegfilgrastim Biosimilar Approved.
Aschenbrenner DS
Am J Nurs; 2018 Oct; 118(10):19-20. PubMed ID: 30260881
[No Abstract] [Full Text] [Related]
19. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
20. Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation.
Harada K; Yamada Y; Konishi T; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Yasuda S; Yoshioka K; Watakabe-Inamoto K; Igarashi A; Najima Y; Hagino T; Muto H; Kobayashi T; Doki N; Kakihana K; Sakamaki H; Ohashi K
Int J Hematol; 2016 Dec; 104(6):709-719. PubMed ID: 27565504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
